To elucidate the prognosis of the patients in group I more accurately, the patients in group I were further classified into two subgroups based on age, serum CRP levels prior to commencing molecular targeted therapy, prior nephrectomy, first-line drug treatment, bone metastasis and the number of metastatic organs. This evidence concerns the gene CRP and bone metastasis.